Pinealon (20mg)

Description

Pinealon (Glu-Asp-Arg; EDR) is a synthetic tripeptide bioregulator developed from pineal gland research by Vladimir Khavinson’s group at the Saint Petersburg Institute of Bioregulation and Gerontology. As part of the cytomedine class of short peptide bioregulators, Pinealon is studied for its neuroprotective effects and its ability to penetrate the blood-brain barrier and influence gene expression in neural tissue.

Why Researchers Select Pinealon

The EDR tripeptide demonstrates a consistent pattern in Khavinson’s research program: short peptides derived from specific organs exhibit tissue-specificity in gene regulation and can interact with DNA promoter regions to influence transcription of target genes. For Pinealon specifically, research has examined neuroprotective effects in hypoxia and oxidative stress models, influence on BDNF and NGF expression in neural cells, and modulation of serotonin and melatonin metabolism pathways — consistent with its pineal gland origin. It is frequently studied alongside Epithalon (pineal-derived) and Selank/Semax (neuropeptide research).

Common Research Applications

• Neuroprotection in hypoxia and oxidative stress models
• BDNF and NGF expression modulation studies
• Pineal gland and melatonin pathway research
• Short peptide DNA binding and gene regulation studies
• Comparative cytomedine bioregulator research

Molecular Profile

• Sequence: Glu-Asp-Arg | MW: ~418.4 g/mol | Purity: ≥98% HPLC | Form: Lyophilized

For Research Use Only. Not for human or veterinary use.